In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine
Yahoo! Finance
Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
BNN
AION Labs, collaborating with industry leaders, invites innovators to join their mission in leveraging AI and ML to target RNA for small molecule therapeutics. This initiative could redefine drug discovery and benefit global health.
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
PR Newswire
Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules”
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
PharmiWeb
Israel-Based Venture Studio Comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) Seeks Global Research and Technology Talent to Form New Startup Focused on: “AI/ML Platform for Targeting RNA with Small Molecules“
BioMed X Launches a New Call for Application in Autoimmune Disease Research
Yahoo! Finance
BioMed X, a biomedical research institute, announced the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.
BioMed X Launches a New Call for Application in Autoimmune Disease Research
MarketWatch
BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune disease.
BioMed X and AbbVie Start New Research Project in the USA
Yahoo! Finance
BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be hosted by the new BioMed X Institute in New Haven, CT, USA. The project aims to generate an organotypic human arterial model with sufficient complexity to recapitulate key characteristics of chronic autoimmune disease onset, progression, and resolution, with the long-term…
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Yahoo! Finance
BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations…